MyMD Pharmaceuticals Files 8-K on Security Holder Rights
Ticker: QCLS · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update, legal-amendment
Related Tickers: MYMD
TL;DR
MYMD filed an 8-K on 6/17, changes to shareholder rights and bylaws. Check for details.
AI Summary
MyMD Pharmaceuticals, Inc. filed an 8-K on June 17, 2024, reporting material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits. The company was formerly known as Akers Biosciences, Inc. and changed its name on April 13, 2017.
Why It Matters
This filing indicates significant changes in the company's corporate structure or security holder agreements, which could impact investors' rights and the company's governance.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and amendments to governing documents can introduce new risks or alter existing ones for investors.
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- Akers Biosciences, Inc. (company) — Former company name
- June 17, 2024 (date) — Date of earliest event reported
- April 13, 2017 (date) — Date of name change
FAQ
What specific modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the provided text excerpt. Further review of the full filing is required.
What amendments were made to the company's articles of incorporation or bylaws?
The filing states that there were amendments to the articles of incorporation or bylaws. The exact nature of these amendments is not detailed in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 17, 2024.
What was MyMD Pharmaceuticals, Inc. formerly known as?
MyMD Pharmaceuticals, Inc. was formerly known as Akers Biosciences, Inc.
On what date did the company change its name from Akers Biosciences, Inc.?
The company changed its name from Akers Biosciences, Inc. on April 13, 2017.
Filing Stats: 773 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-06-24 16:23:01
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
- $1,000 — Preferred Stock, with a stated value of $1,000 per share (the "Preferred Stock"), and
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex3-1.htm (EX-3.1) — 13KB
- 0001493152-24-024960.txt ( ) — 228KB
- mymd-20240617.xsd (EX-101.SCH) — 3KB
- mymd-20240617_lab.xml (EX-101.LAB) — 33KB
- mymd-20240617_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: June 24, 2024 By: /s/ Mitchell Glass, M.D. Name: Mitchell Glass, M.D. Title: President and Chief Medical Officer